MHRA says caution is required due to cardiac risks (QT interval prolongation) and warns of a potential drug interaction with rivaroxaban.

MHRA issues update on known risk of infantile hypertrophic pyloric stenosis.

Small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk.